Drug intelligence / Profile preview

SEA-CD40 + pembrolizumab + pemetrexed + carboplatin

Development stage: Unknown
Lead developer: Pfizer
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

This is a **four-drug combination regimen** consisting of SEA-CD40 (a monoclonal antibody agonist of CD40), pembrolizumab (a PD-1 immune checkpoint inhibitor), pemetrexed (a folate antimetabolite chemotherapy), and carboplatin (a platinum-based chemotherapy). SEA-CD40 binds CD40, amplifying immune activation and antitumor activity. Pembrolizumab blocks PD-1, releasing T-cell inhibition. Pemetrexed inhibits folate-dependent enzymes involved in DNA synthesis, and carboplatin causes DNA crosslinking and apoptosis. This combination is under clinical investigation for non-small cell lung cancer (NSCLC) and other advanced cancers. It is administered intravenously and is designed to augment antitumor immunity alongside standard chemotherapy[7].

Other names: SEA-CD40 + pembrolizumab + pemetrexed + carboplatin

Targets

PDCD1 (Programmed cell death protein 1 receptor)GART (GAR transformylase)FcγRIIIa (Low affinity immunoglobulin gamma Fc region receptor III-A)DHFR (Dihydrofolate reductase)CD40 (Cluster of differentiation 40 receptor)DNATS (Thymidylate synthase)

Beyond the preview

Go deeper on SEA-CD40 + pembrolizumab + pemetrexed + carboplatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SEA-CD40 + pembrolizumab + pemetrexed + carboplatin.

Explore the full profile